Evommune, Inc.

Evommune, Inc. has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. for the worldwide rights (excluding Greater China) to develop, manufacture, and commercialize Hinova's VAV1 degraders, including EVO570. Evommune will pay an upfront fee of $20 million in cash and $10 million in pre-funded warrants, with potential milestone payments of up to $1.1 billion and tiered royalties. Concurrently, Evommune announced a private placement expected to raise approximately $30 million to fund clinical development and general corporate purposes.

Evommune, Inc. reported a net loss of $(32.2) million for the three months ended June 30, 2026, and $(53.9) million for the six months ended June 30, 2026. The clinical-stage biotechnology company increased its research and development expenses significantly year-over-year. In February 2026, the company successfully raised $117.2 million through a private placement of common stock, which is expected to fund operations for at least the next twelve months.

Evommune, Inc. announced the initiation of a Phase 2b clinical trial for its MRGPRX2 inhibitor, EVO756, for the prophylactic treatment of migraine. The trial will enroll approximately 330 adult patients with refractory migraine, evaluating daily doses up to 100 mg over 12 weeks. EVO756 is designed to inhibit three key neuropeptides involved in migraine, with top-line data expected in 2027.

Evommune announced top-line results from its Phase 2b trial evaluating EVO756 for moderate-to-severe chronic spontaneous urticaria (CSU). The study did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. Consequently, the company plans to cease development of EVO756 for CSU. However, Evommune will continue to evaluate EVO756 for other indications, including Atopic Dermatitis and Migraine, with Phase 2b data for Atopic Dermatitis expected in Q3 2026. The company also highlighted positive Phase 2a data for EVO301 in Atopic Dermatitis and a strong cash position through 2028.

Evommune, Inc. reported a net loss of $21.7 million for the three months ended March 31, 2026, an increase from $14.6 million in the prior year. This increased loss was driven by higher research and development and general and administrative expenses, while license revenue ceased. However, the company significantly strengthened its financial position by raising $117.2 million in net proceeds from a private placement of common stock in February 2026. This capital raise led to a substantial increase in cash, investments, and total assets, with management expecting existing capital to fund operations for at least twelve months.

Evommune, Inc. reported its first-quarter 2026 financial results, including a net loss of $21.7 million, compared to $14.6 million in Q1 2025. The company also provided a business update, confirming that top-line Phase 2b data for EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) are on track for June 2026 and Q3 2026, respectively. Evommune plans to initiate a Phase 2b trial for EVO756 in migraine prophylaxis in mid-2026 and a Phase 2b trial for EVO301 in AD in mid-2027, supported by a strong cash position of $307.0 million, expected to fund operations through 2028.

Evommune, Inc. hosted a webcast on April 13, 2026, to discuss the migraine treatment landscape. The presentation highlighted the potential role of MRGPRX2 inhibition in addressing this debilitating condition. This event provides an update on the company's focus within the therapeutic area.